Coronary atherosclerotic heart disease
Conditions
Interventions
Phosphocreatine group:4g phosphocreatine was diluted in 100 mL of 0.9% saline and administered intravenously over a 30-minute period just prior to coronary angiography.
Placebo group:100 mL of 0.9% saline administered intravenously over a 30-minute period just prior to coronary angiography.
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) There are typical symptoms of angina pectoris and the exclusion of aortic valve disease or a clear history of myocardial infarction or a clear history of acute myocardial infarction; 2) Coronary angiography (CAG) found more than 70% of coronary artery stenosis; 3) Hospitalized patients in our hospital; 4) 60 years of age or older patients with coronary heart disease; 5) All the subjects or their guardians must sign the consent form before entering the trial.
Exclusion criteria
Exclusion criteria: 1) Suffering from simple severe valvular stenosis (aortic valve, mitral valve), hypertrophic or restrictive cardiomyopathy; 2) Allergy to contrast dye or phosphocreatine; 3) Past history of chronic kidney disease or preoperative examination revealed GFR<30ml/min; 4) Before and during the study, the application of renal toxicity drugs was used; 5) Systolic blood pressure lower than 13.3kPa; 6) Cardiac shock, insufficient blood volume or unable to use blood vessel dilation agents; 7) Had participated in other clinical studies within 7 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NGAL;Scr;BUN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cys-C;mAlb;cTnI;CK-MB; | — |
Countries
China
Contacts
Public ContactYanqiu Xing
Outcome results
None listed